Barclays
TENX icon

Barclays’s Tenax Therapeutics TENX Stock Holding History

Barclays’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$117K Sell
8,054
-8,644
-52% -$110K ﹤0.01% 3971
2026
Q1 		$267K Buy
+16,698
New +$226K ﹤0.01% 3528
2025
Q3 		– Sell
-11
Closed -$63 – 5727
2025
Q2 		$63 Buy
+11
New +$64 ﹤0.01% 5112
2019
Q4 		– Hold
0
– – – 6803
2019
Q3 		– Hold
0
– – – 7119
2019
Q2 		– Hold
0
– – – 7270
2019
Q1 		– Hold
0
– – – 7321
2018
Q4 		– Hold
0
– – – 7318
2014
Q2 		– Hold
0
– -$1K – 7801
2014
Q1 		– Sell
-1
Closed -$198K – 7486
2013
Q4 		$67K Buy
+1
New +$135K ﹤0.01% 5971

Other funds holding TENX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Barclays's TENX Position: Q2 2026 in Review

Barclays reduced its Tenax Therapeutics (TENX) stake by 52% in Q2 2026, selling an estimated $110K and leaving 8,054 shares worth $117K. The position accounts for ﹤0.01% of the portfolio, ranked #3971.

Barclays first reported a position in TENX in Q4 2013 and has held it in 4 quarters since. The position peaked at $267K in Q1 2026. 111 funds tracked by Wall St. Rank hold TENX as of Q2 2026.

  • Barclays held 8,054 shares of Tenax Therapeutics worth $117K as of Q2 2026.
  • Barclays sold 8,644 Tenax Therapeutics shares in Q2 2026, an estimated $110K.
  • Tenax Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3971 holding.
  • Barclays first reported a position in Tenax Therapeutics in Q4 2013 and has held it in 4 quarters since.
  • Barclays's Tenax Therapeutics position peaked at $267K in Q1 2026.
  • 111 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.